A Phase II Trial of ADI-PEG 20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Bone and Soft Tissue Sarcoma
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAS6530
U.S. Govt. ID: NCT03449901
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to learn more about adding the drug ADI-PEG 20 to a standard treatment regimen called gem-tax (the chemotherapy drugs gemcitabine and docetaxel) for subjects with bone and soft tissue sarcoma, and how the addition of ADI-PEG 20 affects the tumors response to treatment and the side effects you experience.
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have confirmed diagnosis of soft tissue sarcoma (STS) that is unresectable or metastatic? Yes No
Have you had at least one previous kind of treatment for your STS? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE